


电子商务亚马逊 FBA 商标医疗消费品



MERGERSCORP

FBA

这家亚马逊 FBA

公司是一流的医疗消费品的创新端到端设计师和销售商。它是一家由多个自主品牌和独家白标产品组成的全球企业，约占美国销售额的 98.5%，国际销售额约占 1.5%。尽管销售主要通过其亚马逊卖家中心和供应商中心账户产生，但该公司在包括自己的网站在内的其他渠道也取得了成功。

其品牌产品的设计和制造质量最高，价格实惠。该公司的产品组合包括 FDA 和 OTC 批准的产品。拥有 134 个活跃的 ASINS，其顶级产品每个都有数以万计的评论，并始终保持高排名。这些产品多年来一直被授予亚马逊的畅销书徽章和亚马逊的选择徽章。

主要优势

- 产品创新、工程和集成卓越功能方面的专业知识
- 长期的产品、物流和供应商经验
- 成功推出新产品的记录以及强大的新产品机会渠道
- 全面的优质高价值产品
- 由经验丰富的管理团队领导的流线型、高效运营
- 有吸引力的财务状况，高利润率和自由现金流

主要优点

- 同比增长
- 巨大的利润
- 强劲的现金流 - 1630 万美元
- 注册商标、专利和版权
- 产品组合包括 FDA 和 OTC 批准的产品
- 在亚马逊上建立品牌……亚马逊卖家中心和供应商中心账户
- 多个品牌
- 多个畅销书，类别领导者
- 500k+ 评论 - 具有数万条评论的多个 ASINS 高产品排名和卖家反馈
- #1 SKU 的成本节约计划正在进行中，这将节省约 200 万美元
- 关键关系-公司与顶级供应商的平均关系期限为 10 年以上
- 大型电子邮件/订阅者列表 - 25,000+
- 该公司经历了同比增长，并受益于高度可扩展的轻资产商业模式，资本支出要求低，自由现金流转换率高。这是一个绝佳的机会，可以利用迄今为止的良好基础

TARGET PRICE

\$115,000,000

GROSS REVENUE

\$69,374,218

EBITDA

\$16,290,139

BUSINESS TYPE

互联网业务

ESTABLISHED

2013-03-01

COMPETITION

公司的竞争优势包括：

多层品牌组合

令人垂涎的采购关系 优质产品

大量评论和高排名

GROWTH & EXPANSION

凭借其巨大的业绩和成功，有很大的机

添加额外的 DME

产品——仅在亚马逊上，这就是一个价

10 亿美元的市场

添加其他诊断产品

输入相邻的产品类别

扩大地域分布

COUNTRY

美国

BUSINESS ID

L#20220258

和巨大成功来扩展这些品牌的全部潜力。

由于公司的规模和能力以及应卖方要求以保持更高级别的机密性，我们只能在收到我们的买方信息表和此列表特定的附加 NDA

后披露业务信息。经询问，您将收到我们的买方信息表以代替招股说明书。收到后，我们可以随后转发 NDA 和招股说明书以供审查。

请问您是否是对该列表有浓厚兴趣的买家，并且可以执行数百万美元收购这种规模的亚马逊企业。

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM